Clinical Trial Update: Double-T - Improving Outcomes in High-risk 2nd Line Relapsed/Refractory Large B-Cell Lymphoma Patients Eligible for CAR-T-cell Therapy With a Glofitamab-based Induction and Consolidation Concept [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a glofitamab-based induction and consolidation strategy for high-risk second-line relapsed/refractory diffuse large B-cell lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Relapsed /Refractory DLBCL | Phase 2 | Status: NOT_YET_RECRUITING